Skip to content

Clinical trial of human (allogeneic) iPS cell-derived cardiomyocytes sheet for dilated cardiomyopathy

Clinical trial of human (allogeneic) iPS cell-derived cardiomyocytes sheet for dilated cardiomyopathy

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2053230136
Enrollment
4
Registered
2023-11-25
Start date
2024-05-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dilated cardiomyopathy

Interventions

Sponsors

Miyagawa Shigeru
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) dilated cardiomyopathy 2) NYHA class 3,4 3) Patients who can not expect symptomatic improvement with standarid treatment for taget disease.To be recognized by the third party committee with experts. 4) Patients who have not seen improvement in cardiac function more than 3 months after standard surgical treatment and who are at risk of worsening heart failure 5) Ejecion franction<40% 6) Patients who can obtain written consent from the subject to participate in the clinical trial. 7) Patients who can continue to visit the study site for 52 weeks after transplantation

Exclusion criteria

Exclusion criteria: 1) Autoimmune disease 2) Allergic or hypersensitive to the immunosuppressant 3) Severe infection 4) Persistent shock due to worsening heart failure 5) Irreversible organ failure other than heart 6) Malignancy 7) Pregnancy 8) Alcoholic or drug addiction in recent six months 9) Allergies or hypersensitivity to animals from which raw materials used 10) Severe pulmonary hypertension 11) Within 6 months after participating in the clinical trial 12) Patients deemed unsuitable as subjects

Design outcomes

Primary

MeasureTime frame
Number and frequency of the following items that occur up to 52 weeks after transplantation 1) Adverse events and malfunctions 2) Serious adverse events 3) Vital signs, general blood tests, blood biochemistry tests, tumor marker tests and safety-related evaluations 4) Incidence of cardiac clinical events such as death and hospitalization

Secondary

MeasureTime frame
1) Contractile function of the left ventricle 2) left ventricular remodeling 3) Severity of heart failure 4) Exercise tolerance 5) Blood test value trends 6) Cumulative number of rejection reactions 7) Number of patients judged to have improved at 26 or 52 weeks after transplantation

Contacts

Public ContactTakuji Kawamura

Osaka university hospital

saisentan@tissue.med.osaka-u.ac.jp+81-6-6879-3154

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026